摘要
目的:研究重组人表皮生长因子加双料喉风散对头颈恶性肿瘤放射性口腔粘膜炎的防治效果。方法:96例接受放射治疗的头颈恶性肿瘤患者随机分为预防组、治疗组、对照组,每组32例,预防组在放疗开始时预防性用药,治疗组在出现放射性口腔粘膜炎时开始治疗性用药,对照组采用常规处理。结果:预防性用药组的急性放射性口腔粘膜炎出现较晚,多在放射治疗>10Gy后出现((22/32);而对照组多出现在10Gy时(26/32),预防组、治疗组和对照组Ⅲ、Ⅳ度放射性口腔粘膜炎的发生率分别是34.38%,37.50%,78.13%,预防组和治疗组的Ⅲ、Ⅳ度放射性口腔粘膜炎的发生率均低于对照组,预防组和治疗组的放射性口腔粘膜炎平均治愈时间也较对照组短。结论:重组人表皮生长因子加双料喉风散预防用药可推迟放射性口腔粘膜炎的发生,预防用药和治疗用药均可降低Ⅲ、Ⅳ度放射性口腔粘膜炎的发生率,并可促进放射性口腔粘膜炎的愈合,缩短治疗时间。
Objective：To study the preventive and therapeutic effects of a combine therap with Recombinant Human Epidermal Growth Fator（rhEGF） plus ShangLiao Houfengsan on tumors of the head and neck radiation effects of oral mucositis. Methods： From March 2005 to June 2007 treated in our hospital for radiotberapy for head and neck cancer patients, with 96 patients were randomly divided into the prevention group, the treatment group and the control group,32 patients in each group, the prevention group in radiotherapy at the beginning of preventive medicine, the treatment group receiving this combined therapy begin when the symptoms of oral mucositis appearing following radiation treatment, the control group using conventional treatment. Results：preventive treatment of acute radiation stomatitis group appeared late in the radiation therapy 10 Gy after （22/32）, while the control group appeared in more than 10 Gy（26/32）, the prevention group, the treatment group and control group Ⅲ, Ⅳ incidence rate is 34.38%, 37.50% and 78.13% ,prevention group and the treatment group Ⅲ, Ⅳ radioactive oral mucositis incidence rate lower than the control group. prevention group and the treatment group radioactive oral mucositis average healing time shorter than that of the control group. Conclusions：combined rhGEF plus Shangliaohoufengsan for preventive medication may be deferred radioactive oral mucositis incidence, prevention and treatment of drug use can be reduced Ⅲ, Ⅳ radioactive oral mucositis incidence rate and promote the healing of oral mucositis, shortened treatment time.
出处
《赣南医学院学报》
2008年第3期363-364,384,共3页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
